


## Laurotetanine

Cat. No.:	HY-117616
CAS No.:	128-76-7
Molecular Formula:	C <sub>19</sub> H <sub>21</sub> NO <sub>4</sub>
Molecular Weight:	327.37
Target:	NF-κB
Pathway:	NF-κB
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Laurotetanine ((+)-Laurotetanine) is a potent and orally active isoquinoline alkaloid and could be extracted from the roots of <i>Litsea cubeba</i> (Lour.) Pers. Laurotetanine exerts an anti-asthmatic effect by inhibition of IgE, histamine, and inflammatory reactions via down-regulating MUC5AC and NF-κB signaling pathways <sup>[1]</sup> .								
<b>In Vivo</b>	<p>Laurotetanine ((+)-Laurotetanine; 20-60 mg/kg; p.o.; daily, for 21 d; Sprague Dawley (SD) rats) has anti-asthmatic effect in rats by down-regulating MUC5AC and NF-κB signaling pathways<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Sprague Dawley (SD) rats (180-220g)<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>20, 40, and 60 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral administration; daily, for 21 days</td> </tr> <tr> <td>Result:</td> <td>           Reduced inflammatory cells, including eosinophils, neutrophils, lymphocytes, and macrophages.            Decreased inflammatory cytokines viz IL-4, IL-6, IL-13 and increased IFN-γ.            Reduced serum IgE and histamine.            Decreased MUC5AC expression and increased NF-κB and IκB expression in lung tissues.         </td> </tr> </table>	Animal Model:	Sprague Dawley (SD) rats (180-220g) <sup>[1]</sup>	Dosage:	20, 40, and 60 mg/kg	Administration:	Oral administration; daily, for 21 days	Result:	Reduced inflammatory cells, including eosinophils, neutrophils, lymphocytes, and macrophages. Decreased inflammatory cytokines viz IL-4, IL-6, IL-13 and increased IFN-γ. Reduced serum IgE and histamine. Decreased MUC5AC expression and increased NF-κB and IκB expression in lung tissues.
Animal Model:	Sprague Dawley (SD) rats (180-220g) <sup>[1]</sup>								
Dosage:	20, 40, and 60 mg/kg								
Administration:	Oral administration; daily, for 21 days								
Result:	Reduced inflammatory cells, including eosinophils, neutrophils, lymphocytes, and macrophages. Decreased inflammatory cytokines viz IL-4, IL-6, IL-13 and increased IFN-γ. Reduced serum IgE and histamine. Decreased MUC5AC expression and increased NF-κB and IκB expression in lung tissues.								

### REFERENCES

[1]. Xin XX, et, al. Anti-asthmatic effect of laurotetanine extracted from *Litsea cubeba* (Lour.) Pers. root on ovalbumin-induced allergic asthma rats, and elucidation of its mechanism of action. *TROP J PHARM RES.* 2019;18(6).

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA